143 related articles for article (PubMed ID: 20552573)
1. Immune reconstitution of B-cell lymphoma patients receiving CHOP-based chemotherapy containing rituximab.
Kurokawa T; Hase M; Tokuman N; Yoshida T
Hematol Oncol; 2011 Mar; 29(1):5-9. PubMed ID: 20552573
[TBL] [Abstract][Full Text] [Related]
2. Delayed hepatitis B virus reactivation after cessation of preemptive lamivudine in lymphoma patients treated with rituximab plus CHOP.
Dai MS; Chao TY; Kao WY; Shyu RY; Liu TM
Ann Hematol; 2004 Dec; 83(12):769-74. PubMed ID: 15338194
[TBL] [Abstract][Full Text] [Related]
3. Risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen negative/hepatitis B core antibody positive patients receiving rituximab-containing combination chemotherapy without routine antiviral prophylaxis.
Koo YX; Tay M; Teh YE; Teng D; Tan DS; Tan IB; Tai DW; Quek R; Tao M; Lim ST
Ann Hematol; 2011 Oct; 90(10):1219-23. PubMed ID: 21520001
[TBL] [Abstract][Full Text] [Related]
4. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
Coiffier B; Lepage E; Briere J; Herbrecht R; Tilly H; Bouabdallah R; Morel P; Van Den Neste E; Salles G; Gaulard P; Reyes F; Lederlin P; Gisselbrecht C
N Engl J Med; 2002 Jan; 346(4):235-42. PubMed ID: 11807147
[TBL] [Abstract][Full Text] [Related]
5. [Hepatitis B virus reactivation after cessation of prophylactic lamivudine therapy in B-cell lymphoma patients treated with rituximab combined CHOP therapy].
Mimura N; Tsujimura H; Ise M; Sakai C; Kojima H; Fukai K; Yokosuka O; Takagi T; Kumagai K
Rinsho Ketsueki; 2009 Dec; 50(12):1715-9. PubMed ID: 20068280
[TBL] [Abstract][Full Text] [Related]
6. Dose-dense R-CHOP-14 supported by pegfilgrastim in patients with diffuse large B-cell lymphoma: a phase II study of feasibility and toxicity.
Brusamolino E; Rusconi C; Montalbetti L; Gargantini L; Uziel L; Pinotti G; Fava S; Rigacci L; Pagnucco G; Pascutto C; Morra E; Lazzarino M
Haematologica; 2006 Apr; 91(4):496-502. PubMed ID: 16537117
[TBL] [Abstract][Full Text] [Related]
7. [Comparison between R-CHOP regimen and CHOP regimen in treating naive diffuse large B-cell lymphoma in China--a multi-center randomized trail].
Lin TY; Zhang HY; Huang Y; Guan ZZ; Shen T; Shi YK; Zhu J; Ke XY; Wang HQ; Shen ZX; Yu SY; Liu T; Shi XL
Ai Zheng; 2005 Dec; 24(12):1421-6. PubMed ID: 16351785
[TBL] [Abstract][Full Text] [Related]
8. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjögren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas.
Voulgarelis M; Giannouli S; Anagnostou D; Tzioufas AG
Rheumatology (Oxford); 2004 Aug; 43(8):1050-3. PubMed ID: 15187246
[TBL] [Abstract][Full Text] [Related]
9. VNCOP-B plus rituximab therapy in elderly patients with aggressive B-cell non-Hodgkin lymphoma: a multicenter experience.
Ishii K; Urase F; Nagare Y; Kimura H; Manabe M; Yagi T; Teshima H; Hayashi K; Shibano M; Tsukaguchi M; Katsurada T; Mugitani A; Kitayama H; Nomura S
Arch Gerontol Geriatr; 2010; 51(2):209-15. PubMed ID: 19926148
[TBL] [Abstract][Full Text] [Related]
10. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.
Habermann TM; Weller EA; Morrison VA; Gascoyne RD; Cassileth PA; Cohn JB; Dakhil SR; Woda B; Fisher RI; Peterson BA; Horning SJ
J Clin Oncol; 2006 Jul; 24(19):3121-7. PubMed ID: 16754935
[TBL] [Abstract][Full Text] [Related]
11. Improved therapeutic outcomes of DLBCL after introduction of rituximab in Korean patients.
Park YH; Lee JJ; Ryu MH; Kim SY; Kim DH; Do YR; Lee KH; Oh SJ; Kim YK; Suh CW; Heo DS; Ryoo BY; Kim JK; Song HS; Lee WS; Kim HJ; Bang YJ; Yang SH; Sohn SK; Kang YK;
Ann Hematol; 2006 Apr; 85(4):257-62. PubMed ID: 16416337
[TBL] [Abstract][Full Text] [Related]
12. Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP.
Lin PC; Hsiao LT; Poh SB; Wang WS; Yen CC; Chao TC; Liu JH; Chiou TJ; Chen PM
Ann Hematol; 2007 Feb; 86(2):95-100. PubMed ID: 17031689
[TBL] [Abstract][Full Text] [Related]
13. One single dose of rituximab added to a standard regimen of CHOP in primary treatment of follicular lymphoma appears to result in a high clearance rate from circulating bcl-2/IgH positive cells: Is the end of molecular monitoring near?
Schmitt C; Grundt A; Buchholtz C; Scheuer L; Benner A; Hensel M; Ho AD; Leo E
Leuk Res; 2006 Dec; 30(12):1563-8. PubMed ID: 16530831
[TBL] [Abstract][Full Text] [Related]
14. [Comparison of rituximab plus CHOP regimen and CHOP regimen alone for treatment of newly diagnosed patients with diffuse large B-cell lymphoma].
Wu HJ; Zhang QY; Chen DF; Guan XJ; Zhang BL; Ma J
Ai Zheng; 2005 Dec; 24(12):1498-502. PubMed ID: 16351800
[TBL] [Abstract][Full Text] [Related]
15. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab.
Yeo W; Chan TC; Leung NW; Lam WY; Mo FK; Chu MT; Chan HL; Hui EP; Lei KI; Mok TS; Chan PK
J Clin Oncol; 2009 Feb; 27(4):605-11. PubMed ID: 19075267
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy of CHOP+/-Rituximab-like therapy plus radiation therapy for patients with diffuse large B-cell lymphoma stage I].
Ueda K; Yokoyama M; Asai H; Koudaira M; Yamada S; Katsube A; Mishima Y; Sakajiri S; Takeuchi K; Saotome T; Terui Y; Takahashi S; Hatake K
Gan To Kagaku Ryoho; 2010 May; 37(5):853-7. PubMed ID: 20495315
[TBL] [Abstract][Full Text] [Related]
17. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
18. [Comparative analysis of liver function in HBsAg-/HBcAb+ patients with diffuse large B-cell lymphoma treated with CHOP and R-CHOP regimens].
Huang YH; He XH; Qin Y; Yang S; Lü Z; Dong M; Zhou SY; Liu P; Zhang CG; Yang JL; Shi YK
Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):385-9. PubMed ID: 22883463
[TBL] [Abstract][Full Text] [Related]
19. Analysis of hepatitis B surface antibody titers in B cell lymphoma patients after rituximab therapy.
Pei SN; Ma MC; Wang MC; Kuo CY; Rau KM; Su CY; Chen CH
Ann Hematol; 2012 Jul; 91(7):1007-12. PubMed ID: 22273839
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and toxicity of 2 schedules of frontline rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone plus bortezomib in patients with B-cell lymphoma: a randomized phase 2 trial from the French Adult Lymphoma Study Group (GELA).
Ribrag V; Gisselbrecht C; Haioun C; Salles G; Golfier JB; Ertault M; Ferme C; Briere J; Brice P; Mounier N
Cancer; 2009 Oct; 115(19):4540-6. PubMed ID: 19593797
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
